Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 16:12:22.
doi: 10.1186/s13098-020-00529-z. eCollection 2020.

Time in range: a new parameter to evaluate blood glucose control in patients with diabetes

Monica Andrade Lima Gabbay  1 , Melanie Rodacki  2 , Luis Eduardo Calliari  3 , Andre Gustavo Daher Vianna  4 , Marcio Krakauer  5 , Mauro Scharf Pinto  4 , Janice Sepúlveda Reis  6 , Marcia Puñales  7 , Leonardo Garcia Miranda  8 , Ana Claudia Ramalho  9 , Denise Reis Franco  10 , Hermelinda Pedrosa Cordeiro Pedrosa  11
Affiliations
Review

Time in range: a new parameter to evaluate blood glucose control in patients with diabetes

Monica Andrade Lima Gabbay et al. Diabetol Metab Syndr. .

Abstract

The International Consensus in Time in Range (TIR) was recently released and defined the concept of the time spent in the target range between 70 and 180 mg/dL while reducing time in hypoglycemia, for patients using Continuous Glucose Monitoring (CGM). TIR was validated as an outcome measures for clinical Trials complementing other components of glycemic control like Blood glucose and HbA1c. The challenge is to implement this practice more widely in countries with a limited health public and private budget as it occurs in Brazil. Could CGM be used intermittently? Could self-monitoring blood glucose obtained at different times of the day, with the amount of data high enough be used? More studies should be done, especially cost-effective studies to help understand the possibility of having sensors and include TIR evaluation in clinical practice nationwide.

Keywords: Continuous glucose monitoring; Glycated hemoglobin; Hypoglycemia; Time in range.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

References

    1. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diab Care. 2019;1(42):1593–1603. doi: 10.2337/dci19-0028. - DOI - PMC - PubMed
    1. Nathan DM and for the DCCT/EDIC Research group The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diab Care. 2014;37:9–16. doi: 10.2337/dc13-2112. - DOI - PMC - PubMed
    1. El-Laboudi AH, Godsland IF, Johnston DG, Oliver NS. Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diab Technol Ther. 2016;18:806–812. doi: 10.1089/dia.2016.0146. - DOI - PubMed
    1. Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diab Technol Ther. 2017;19:S16–S26. doi: 10.1089/dia.2017.0029. - DOI - PMC - PubMed
    1. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using hba1c alone to assess glycemic control can be misleading. Diab Care. 2017;40:994–999. doi: 10.2337/dc17-0636. - DOI - PMC - PubMed